RAPAMYCIN FOR TREATING LYMPHANGIOLEIOMYOMATOSIS

摘要

FIELD: medicine; pharmaceuticals.;SUBSTANCE: present invention relates to a dry powder pharmaceutical composition for pulmonary delivery for treating lymphangioleiomyomatosis in a human in need thereof. Composition contains micronised rapamycin, carrier particles, wherein carrier comprises a mixture of two different lactose carriers, and one or more optional excipients selected from a phospholipid and a metal salt of a fatty acid. Micronised rapamycin has mass median aerodynamic diameter (MMDA) from 1 to 5 microns. Rapamycin is the only therapeutic substance in the composition. Dry powder of rapamycin is delivered by inhaler. Also described is a method of treating lymphangioleiomyomatosis by inhalation of a dry powdered rapamycin composition.;EFFECT: composition according to the invention provides high local concentration of rapamycin in lung tissue with an inhalation route.;18 cl, 8 dwg, 9 tbl, 7 ex